FDNA Releases a Multi-Platform Version of Face2Gene, a Genetic Search and Reference Solution at ACMG 2015

NEW YORK, March 25, 2015 /PRNewswire/ --

FDNA®, the pioneer in computer-aided dysmorphology analysis, has released today version 4 of Face2Gene, allowing geneticists around the globe to access Facial Dysmorphology Novel Analysis from computers, as well as mobile devices. Face2Gene® facilitates detection of facial dysmorphic features and recognizable patterns of human malformations to present comprehensive and up-to-date genetic references. The date of the release coincides with the Annual Clinical Genetics Meeting, ACMG 2015, in Salt Lake City, UT, where attendees can experience FDNA's new offering at booth #811.

"I am excited to be a part of the FDNA community, promoting broad information sharing with my peers to amplify the scientific and clinical value of our community's accumulated knowledge for the purpose of efficiently diagnosing individuals with rare genetic disorders." said Dr. Karen W. Gripp. Chief, Division of Medical Genetics, A.I. DuPont Hospital for Children.

This new version of Face2Gene also incorporates the much-anticipated Online Unknown Forum dedicated to the discussion and review of undiagnosed and challenging cases. FDNA will unveil this forum in a theater presentation during ACMG 2015 on Thursday March 26^th, 2015 at 11:40 am.

"We are excited to allow access to Face2Gene from all devices and showcase our technology at this prestigious venue. This fourth version of Face2Gene demonstrates our commitment to the community of genetics professionals. We will continue to work diligently to improve and add new features to Face2Gene," said Dekel Gelbman, FDNA's Chief Executive Officer.

About FDNA

Face2Gene® is a genetic search and reference solution powered by FDNA® (Facial Dysmorphology Novel Analysis) technology. Face2Gene facilitates detection of facial dysmorphic features and recognizable patterns of human malformations to present comprehensive and up-to-date genetic references. Face2Gene aids and empowers in accelerating and increasing confidence in the research and investigation of genetic syndromes. The solution leverages advanced algorithms and the cumulative experience of hundreds of genetics professionals and tens of thousands of analyzed cases. FDNA's technology improves over time, referencing comprehensive phenotype databases in real-time. For more information, please visit http://www.FDNA.com

Media contact:
FDNA Inc.
Yaron Front
V.P. Marketing
[email protected]
+1-347-305-0076

SOURCE FDNA